Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Reprod. Health

Sec. HIV and STIs

Volume 7 - 2025 | doi: 10.3389/frph.2025.1529067

Implementation Strategies to Support Pre-Exposure Prophylaxis for HIV Prevention (PrEP) Care for Cisgender Women in Federally-Funded Family Planning Clinics in Atlanta, Georgia

Provisionally accepted
Katherine  M AndersonKatherine M Anderson1Lily  V BonadonnaLily V Bonadonna2Elora  J CortesElora J Cortes1Deja  L ErDeja L Er2Celeste  K EllisonCeleste K Ellison1Peyton  WilliamsPeyton Williams3,4Sara  S SullivanSara S Sullivan3,4Michael  W BrooksMichael W Brooks3,4Anandi  ShethAnandi Sheth2Jessica  McDermott SalesJessica McDermott Sales1*
  • 1Department of Behavioral, Social and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, United States
  • 2School of Medicine, Emory University, Atlanta, Georgia, United States
  • 3The Family Health Centers of Georgia, Altanta, United States
  • 4Georgia Family Planning System, Atlanta, United States

The final, formatted version of the article will be published soon.

Title X-funded family planning clinics stand to play a significant role in Ending the HIV Epidemic (EHE), as a unique access point for cisgender women in the U.S. who account for approximately 1 in 5 new HIV infections. Biomedical HIV prevention, known as PrEP, is effective for cisgender women, yet uptake remains low and rates of new infections among women have remained steady while other key populations have experienced declines. Further, significant racial disparities persist in PrEP uptake and HIV acquisition, with Black women accounting for almost 60% of new cases. Low risk perception, lack of knowledge, and insufficient access to biomedical HIV prevention in sexual health service settings contribute to this. Despite receiving federal funds to provide free and low-cost family planning and preventative sexual health services, Title X clinics do not routinely provide PrEP as part of their services; this excludes the millions of U.S. women who engage in sexual behaviors aligned with HIV risk from access to effective prevention when utilizing Title X clinics for care. In the course of developing a systems-level bundle of tailored implementation strategies to support PrEP care delivery in Title X-funded family planning clinics, we conducted a series of baseline focus groups with staff and providers at Title X family planning clinics located in 4 EHE priority jurisdictions that comprise metro Atlanta. The analysis of these focus groups aimed to elucidate important considerations and needs to inform implementation strategy development and strengthen PrEP care delivery in these safety-net clinics. This article describes the findings from these focus groups and recommendations and next steps for scaling PrEP in Title X family planning clinics in the Southern U.S. to improve PrEP reach among cisgender women.

Keywords: hiv prevention, PrEP, Family planning, Title X, cisgender women

Received: 12 May 2025; Accepted: 18 Aug 2025.

Copyright: © 2025 Anderson, Bonadonna, Cortes, Er, Ellison, Williams, Sullivan, Brooks, Sheth and Sales. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jessica McDermott Sales, Department of Behavioral, Social and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.